Regulus Therapeutics Inc 's ROA from the first quarter of 2025 to the first quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Regulus Therapeutics Inc 's ROA in the first quarter of 2025?
Regulus Therapeutics Inc recorded a cumulative net loss of $-48 million during 12 months ending in the first quarter of 2025, resulting in a negative return on assets (ROA) of -53.88%.

However, within the Healthcare sector 638 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2025 quarter, so far to 4193, from total ROA ranking in the fourth quarter of 2024 at 4769.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter
Y / Y Total Assets Change	-35.96 %	148.54 %	156.7 %	148.11 %	223.91 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-48	-46	-42	-35	-31
Return On Assets (TTM)	-53.88 %	-47.1 %	-48.42 %	-49.27 %	-55.7 %
RGLS's Total Ranking	# 4193	# 4769	# 4234	# 4272	# 4412
Total Assets (TTM) in million	73	83	93	104	114
Seq. Total Assets Change	-12.57 %	-10.17 %	-10.76 %	-8.63 %	239.31 %
Seq. Net Income Change	-	-	-	-	-

RGLS's 5 Years Annual ROA >> Back to RGLS Management Effectiveness >> Compare RGLS ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 290
Sector	# 639
Overall	# 4137

Return On Assets Statistics
High	Average	Low
-16.85 %	-58.97 %	-112.01 %
(Dec 31 2013)		(Dec 31 2018)

Financial Statements
Regulus Therapeutics Inc 's Assets	$ 73 million	RGLS's Balance sheet
Regulus Therapeutics Inc 's Income	$ -10 million	Quarterly RGLS's Income Statement
RGLS's Income by Division		See RGLS's Income by Division

Annual Return On Assets	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020
Y / Y Total Assets Change	148.54 %	-28.25 %	-33.18 %	62.26 %	2.39 %
Total Assets in million	83	34	47	70	43
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-46	-30	-28	-28	-16
Annual Return On Assets	-55.65 %	-89.61 %	-60.63 %	-39.78 %	-36.51 %

RGLS's 5 Years Annual ROA >> Back to RGLS Management Effectiveness >> Compare RGLS ROA to its Competitors

More Return On Assets Ratios
RGLS's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RGLS's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RGLS's Competitors
Subscribers only: Roa for Regulus Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for RGLS's Customers

You may also want to know
RGLS's Roi	RGLS's Inventory Turnover Ratio	RGLS's Growth Rates	RGLS's Dividend Comparisons
	RGLS's Profitability Ratios	RGLS's Asset Turnover Ratio	RGLS's Dividend Growth
RGLS's Roe	RGLS's Valuation Ratios	RGLS's Financial Strength Ratios	RGLS's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2025, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:22:15+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.